Full-Time

Quality Complaint Management

Deadline 10/31/26
Opella

Opella

5,001-10,000 employees

Global OTC & VMS self-care manufacturer

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
Power BI
Microsoft Office
GMP
Quality Assurance (QA)
Excel/Numbers/Sheets
PowerPoint/Keynote/Slides

Get referred to Opella

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in Pharmacy, Life Sciences, Chemistry, Microbiology, Biotechnology, or a related scientific discipline is required.
  • A minimum of 5 years of experience in Quality Assurance, Quality Systems, Complaint Management, Manufacturing Quality, or a regulated pharmaceutical, consumer healthcare, medical device, or life sciences environment is required.
  • Good understanding of Good Manufacturing Practices, pharmaceutical quality systems, complaint handling, deviation or nonconformance management, corrective and preventive action principles, documentation practices, and data integrity expectations is required.
  • Ability to review technical investigation content, challenge conclusions constructively, identify gaps, and translate findings into clear quality decisions or follow-up actions is required.
  • Strong analytical skills with the ability to interpret quality data, complaint trends, timelines, and recurring issues to support risk-based prioritization and continuous improvement are required.
  • Excellent written and verbal communication skills are required to prepare clear summaries, follow-up communications, quality rationales, and stakeholder updates.
  • Demonstrated ability to manage multiple priorities, meet deadlines, escalate risks appropriately, and work effectively across cultures, functions, and time zones is required.
  • Proficiency in Microsoft Office tools, especially Excel and PowerPoint, is required to prepare metrics, trackers, dashboards, and management-ready summaries.
Responsibilities
  • Manage assigned product quality complaints through the defined lifecycle, including intake review, classification support, investigation follow-up, documentation review, closure readiness, and timely completion within agreed service levels.
  • Coordinate with manufacturing sites, contract manufacturing organizations, affiliate quality teams, medical safety or pharmacovigilance interfaces, supply chain, regulatory, and other cross-functional partners to ensure appropriate ownership, escalation, and resolution of complaint cases.
  • Review investigation reports for completeness, technical rationale, root cause adequacy, batch or product impact assessment, evidence quality, and alignment with applicable procedures and quality expectations.
  • Support risk-based complaint evaluation by identifying potential quality signals, recurring defects, serious or escalated issues, and cases requiring additional investigation, management attention, or linkage to broader quality events.
  • Assess corrective and preventive action proposals for appropriateness, effectiveness, and traceability, and follow up with responsible teams to ensure actions are clearly documented and progressed as required.
  • Maintain data integrity in complaint records, including clear narratives, complete attachments, documented rationale, and audit-ready case files.
  • Monitor complaint timelines, overdue actions, investigation extensions, and recurring follow-up needs, and proactively escalate risks to support timely and compliant case closure.
  • Prepare and analyze complaint metrics, trend reports, dashboards, and management summaries to identify patterns, emerging risks, process bottlenecks, and opportunities for improvement.
  • Contribute to periodic quality reviews, governance forums, and business reviews by providing complaint data, insights, action tracking, and status updates as required.
  • Support audits, inspections, and internal quality assessments by preparing complaint records, responding to information requests, and helping demonstrate process control and traceability.
  • Identify, document, and help implement process improvements that simplify complaint handling, reduce rework, improve stakeholder experience, and strengthen compliance outcomes.
  • Support harmonization of complaint management practices across affiliates and global teams by contributing to guidance documents, training materials, templates, and ways-of-working improvements.
  • Provide stakeholders with clear communication, timely follow-up, practical recommendations, and quality-focused support in day-to-day complaint management activities.
Desired Qualifications
  • Experience using electronic Quality Management Systems such as Veeva Vault QMS, TrackWise, SAP Quality, or comparable complaint and quality platforms.
  • Exposure to global complaint handling processes, outsourced manufacturing or contract manufacturing organization environments, affiliate quality operations, or consumer healthcare quality systems.
  • Experience supporting audits, inspections, quality governance meetings, periodic product reviews, or management review reporting.
  • Working knowledge of complaint interfaces with pharmacovigilance, medical safety, regulatory reporting, product recall, deviations, corrective and preventive action, change control, or product quality review processes.
  • Experience with Power BI, advanced Excel, process mapping, automation, or digital quality transformation initiatives.

Opella produces over-the-counter medicines, vitamins, minerals and supplements for a global audience, with about 100 brands and 11,000 employees. Its products are ready-to-use self-care remedies sold without prescription, covering needs like pain relief, digestion and allergy relief. The company differentiates itself through a large global manufacturing footprint (13 sites) and dedicated science and innovation centers, plus its status as a certified B Corp focused on health for people and the planet. Its goal is to simplify self-care, putting health in people’s hands for half a billion consumers and growing its trusted portfolio through manufacturing excellence and science-backed development.

Company Size

5,001-10,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Neuilly-sur-Seine, France

Founded

2018

Get referred to Opella

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ocoyoacac adds 200 million annual mini-bottles, scaling across Latin America by 2027-2028.
  • Japan’s June 2026 OTC Cialis approval opens a new prescription-free category.
  • Navan expects Opella to cut travel spend 20% and improve 95% adoption.

What critics are saying

  • Fitch rated Opella B+ in February 2026, citing 7.2x leverage and separation costs.
  • Opella still owes about €500 million in IT separation costs through 2028.
  • Brazil’s 2026 Pharmaton forgery alert and Mucosolvan shortages expose brand-control failures.

What makes Opella unique

  • Opella owns 100 loved brands, including Allegra, Doliprane, Enterogermina, and Buscopan.
  • The Mexico plant now makes Enterogermina API and finished product for Americas supply.
  • Opella’s 2026 FIP partnership uniquely links self-care, pharmacists, and health literacy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

76%

1 year growth

76%

2 year growth

26%
Creative Brands
Jul 30th, 2026
Karan Bhatia joins Asahi Group as director-agps.

Karan Bhatia joins Asahi Group as director-agps. Karan Bhatia has transitioned from Sanofi and Opella to join Asahi Group as Director-AGPS. Announcing the move on LinkedIn, he reflected on closing a nine-year chapter with the two organisations, expressing gratitude for the experiences and opportunities gained during his tenure. Karan Bhatia has embarked on a new professional journey, joining Asahi Group as Director-AGPS after nearly a decade with Sanofi and its subsidiary Opella. The development was shared by Bhatia in a LinkedIn update, where he confirmed his departure from the pharmaceutical giant and expressed appreciation for the formative years he spent across the two organisations. "Last week, I closed a professional chapter of nine years with Sanofi & Opella. I'm grateful for my time in these two world-class organisations," he wrote, signalling both the end of a significant tenure and the beginning of a fresh chapter with Asahi Group. Bhatia's move marks a notable shift from the healthcare and pharmaceutical sector to the global beverage industry, underscoring the breadth of his professional expertise and adaptability. Sanofi, a multinational pharmaceutical company headquartered in Paris, and Opella, its consumer healthcare arm, provided him with a platform to contribute to diverse markets and complex business environments. His nine-year association with the two companies reflects a period of sustained growth and leadership, during which he played a role in advancing business strategies and operational excellence. The transition to Asahi Group, a leading Japanese beverage and food company with a strong international footprint, positions Bhatia within a dynamic sector known for innovation and global consumer engagement. As Director-AGPS, he is expected to bring his extensive experience in corporate leadership, strategic planning and cross-sectoral collaboration to strengthen Asahi's global operations. Industry observers note that such cross-sectoral moves are increasingly common among senior executives, reflecting the convergence of skills required across industries. Bhatia's background in healthcare and pharmaceuticals equips him with a unique perspective on consumer needs, regulatory frameworks and international business practices, which are highly relevant to the fast-evolving beverage industry. His announcement has drawn attention within professional circles, with peers and colleagues acknowledging his contributions to Sanofi and Opella while extending best wishes for his new role. The move also highlights the growing trend of leaders leveraging their expertise across diverse industries to drive transformation and growth. For Asahi Group, the appointment underscores its commitment to strengthening leadership capabilities and enhancing its global strategy. For Bhatia, it represents both continuity and change: continuity in his pursuit of impactful leadership, and change in embracing new challenges within a different sector. Discover more from creative brands mag. Brand Management Discover more advertising Business Operations Missing Persons & Abductions July 30, 2026 Discover more Shopping Portals

Mexico Business News
Jul 24th, 2026
The Week in Health: Hospital investment, Cyclospora Outbreak.

The Week in Health: Hospital investment, Cyclospora Outbreak. By Sergio Arturo Lievano Madrigal | Journalist - Fri, 07/24/2026 - 09:59 DIA assistant Mexico's health sector moved on two fronts this week: public infrastructure spending and private manufacturing investment both accelerated, while a cross-border food safety scare tested coordination with the FDA. Meanwhile, a cholesterol drug approval and an insurtech's growth rounded out a week defined by expanding access to care. Ready? This is the Week in Health! Mexico Unveils MX$181 Billion Hospital Infrastructure Plan The government will invest close to MX$181 billion through 2030 to build, expand, or replace 152 public hospitals, growing the IMSS, ISSSTE, and IMSS Bienestar network past 106,000 beds. The plan responds to long-documented funding disparities across Mexico's fragmented public health subsystems. Mexico Modernizes Public Hospitals as Medical Device Market Grows ISSSTE's MX$298 million investment in electric beds and operating room upgrades coincides with LINET Group's new Santa Fe headquarters, signaling sustained demand for medical equipment. Together, the moves point to a multi-front procurement cycle spanning commodity and specialized devices alike. Mexico Investigates Cyclospora Outbreak Mexican authorities activated a joint task force with the FDA to investigate a cyclospora outbreak linked to lettuce from Guanajuato-based supplier Taylor Farms. The case carries real stakes for Mexico's vegetable export sector, which sends nearly 96% of its output to the United States. FDA Approves Merck Oral Pill for High Cholesterol The US FDA approved Lipfendra, Merck's first-in-class oral PCSK9 inhibitor, aimed at the 70% of statin patients who still miss their cholesterol targets. The approval carries relevance for Mexico, where cardiovascular disease remains a leading cause of mortality. Opella Expands Enterogermina Production Line in State of Mexico Opella inaugurated a MX$1.2 billion production line in Ocoyoacac, part of a MX$2.3 billion plan to raise local manufacturing for the domestic market to 80%. The project positions the site as a global backup facility and is expected to create 500 direct and indirect jobs. Disrupting Mexican Healthcare Through Tech-Driven InsurTech Mutuus' Jean-Louis Brunet tells MBN the insurtech now serves 14,000 members through a zero-deductible, direct-payment model targeting Mexico's underserved middle class. He says recent IVA tax changes forced a 23% workforce cut, even as the company grows more than 40% annually.

Logistics Manager
Jul 24th, 2026
Opella inaugurates new $70m-backed production line.

Opella inaugurates new $70m-backed production line. Healthcare company Opella has announced that it has inaugurated a new production line for Enterogermina in Mexico following a US$70 million (c. £52m) investment. Reportedly, the highly automated facility in Ocoyoacac will add an annual capacity of 200 million mini-bottles. It will serve as a complementary regional hub to Opella's plant in Origgio, Italy, and will operate on 100% renewable electrical energy. Opella chief supply chain officer, Rafik Amrane, said: "This new production line in Mexico is a crucial step forward in its broader mission to build a highly resilient, global manufacturing network. "By increasing our production capacity and being closer to the markets we serve, we are fundamentally changing how we deliver care, ensuring that our science-backed solutions are consistently available to the millions of families who rely on them." Following rigorous qualification and regulatory approvals, the new production line will progressively scale operations to bring the product to shelves across the Americas in the 2027-2028 period. Opella Mexico general manager, Luis Soares, said: "With this new production line, Logistics Manager is strengthening Mexico's role as a strategic platform for advanced pharmaceutical manufacturing and exports to Latin America. "It will also enable us to increase the share of Opella products sold in Mexico that are locally manufactured from 60% to 80%, combining stronger, sustainable local production with greater regional reach." IntraLogisteX is taking place in Dallas in 2026, bringing the industry's leading trade show & conference to one of North America's most important logistics hubs. Reuben joined Akabo Media as assistant editor of CiTTi - one of Logistics Manager's sister publications - in October 2023. He has worked in digital and print publications since graduating in MA Publishing in 2022. He holds a great interest in transport technology and innovation. Outside of work, Reuben is also a huge football fan. 24th July 2026 21st July 2026

MEXICONOW
Jul 23rd, 2026
Opella shifts Enterogermina production to Mexico.

Opella shifts Enterogermina production to Mexico. 23 July, 2026 Opella has transferred production of its flagship probiotic Enterogermina from Italy to Mexico, marking a major milestone in the company's manufacturing strategy for the Americas. The move is supported by a US$70 million investment in a new production line at its Ocoyoacac facility in the State of Mexico, part of a broader US$135 million expansion plan running through 2028. The expansion transforms the Ocoyoacac plant into the company's second global manufacturing hub for Enterogermina, complementing its long-established facility in Origgio, Italy. For the first time, the Mexican site will produce both the active pharmaceutical ingredient and the finished product, bringing advanced manufacturing capabilities that were previously concentrated in Europe. The new production line adds an annual capacity of 200 million mini-bottles, enabling Opella to meet growing demand across Latin America while strengthening the resilience of its global supply network. Company executives said producing closer to key markets will improve supply chain efficiency and support faster regional distribution. As production ramps up, the share of Opella products sold in Mexico that are manufactured locally will increase from 60% to 80%. The company also expects the facility to play a larger role as an export platform, supplying multiple Latin American markets from Mexico. Beyond expanding manufacturing capacity, the investment includes a significant transfer of industrial expertise and production technology. According to the company, the project equips the Mexican operation with specialized know-how and quality systems required to manufacture one of the world's leading probiotic brands under the same standards applied in Europe. The Ocoyoacac facility also supports Opella's sustainability objectives. The site operates with 100% renewable electricity, has significantly reduced carbon emissions over the past several years, and follows a zero-waste-to-landfill model, aligning manufacturing expansion with the company's environmental commitments. With the relocation of Enterogermina production, Mexico assumes a more strategic role within Opella's global manufacturing network, reinforcing the country's position as an emerging pharmaceutical production and export hub for the Americas.

The Diplomat
Jul 23rd, 2026
Opella appoints Radu Stănescu as Country Head Romania & Moldova.

Opella appoints Radu Stănescu as Country Head Romania & Moldova. Published on July 23, 2026 Opella, the consumer healthcare company with the third-largest portfolio in the Over the Counter (OTC) and Vitamins, Minerals & Supplements (VMS) market globally, announces the appointment of Radu Stănescu as Country Head for Romania & Moldova. Radu Stănescu brings extensive commercial leadership experience from multinational organizations, including Beiersdorf and Reckitt. Radu Stănescu, Country Head for Romania & Moldova at Opella: "Together with our team, I look forward to building on the strong foundations already in place, serving consumers across Romania and Moldova through our loved brands and working closely with healthcare professionals to empower people to choose health and self-care brands with confidence." In Romania and Moldova, Opella serves consumers with a broad portfolio of health and self-care solutions, including OTC medicines as well as food supplement brands such as Enterogermina and MagneVie. Post Views: 14,698 The first Cobra II tactical armoured vehicles built entirely in Mediaș left the factory... July 24, 2026 PPC Group's entry into the Hungarian energy market, one of Europe's fastest-growing clean energy... July 24, 2026 TeraPlast Group inaugurated its TeraPlast Iberia polyethylene pipe factory in Spain, an important step... July 24, 2026 Rețele Electrice România, part of the PPC group in Romania, has completed the modernization... July 24, 2026 The first Cobra II tactical armoured vehicles built entirely in Mediaș left the factory... July 24, 2026 PPC Group's entry into the Hungarian energy market, one of Europe's fastest-growing clean energy... July 24, 2026 TeraPlast Group inaugurated its TeraPlast Iberia polyethylene pipe factory in Spain, an important step... July 24, 2026